Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC) #Chemicals #Banking #Biotechnology #FinancialServices #InvestmentBanking #NASDAQ #Investing
The Institutional Review Board Has Approved the Increase in Number of Patients from Sixty (60) to Ninety (90).The Company to Expand the Study into Additional Trial Sites in EuropePhiladelphia, Pennsylvania--(Newsfile Corp. - April 21, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce that Institutional Review Board (IRB) has approved the increase in number of patients from sixty (60) to Ninety (90). The phase 2 clinical study (SKNJCT-003) which is...
http://dlvr.it/TKH8QT
http://dlvr.it/TKH8QT
Comments
Post a Comment